September 30, 2021 -- Immunoassay developer Gyros Protein Technologies is introducing a new titer kit called Gyrolab AAV9 to support adeno-associated virus-based cell and gene therapy production.
The company said the new kit enables the rapid determination of physical titer in adeno-associated virus serotype 9 (AAV9) vector-based cell and gene therapy manufacturing. The kit is based on a highly selective AAV9 affinity ligand developed with CaptureSelect technology by Thermo Fisher Scientific.
The AAV9 serotype is attractive as a gene delivery vector owing to its ability to cross the blood-brain barrier and target the central nervous system with high efficiency, Gyros said.
The AAV9 Titer Kit can generate 96 data points in 80 minutes, an improved assay working range compared to ELISA methods. Also, the kit can handle small sample volumes, the company said.
The new kit adds to Gyro's existing range of ready-to-use kits and complements the Gyrolab AAVX Titer Kit, as well as the company's recently launched HEK 293 HCP Solution for Gyrolab (with reagents ordered from Cygnus Technologies).
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
